Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.27)
# 4,402
Out of 5,156 analysts
8
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: In-Line | $73 → $110 | $97.10 | +13.29% | 2 | Mar 5, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $38.22 | +25.59% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $10.45 | +187.08% | 2 | Mar 22, 2023 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $29.65 | +34.91% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $0.73 | +3,039.07% | 1 | May 25, 2021 |
Incyte
Mar 5, 2026
Maintains: In-Line
Price Target: $73 → $110
Current: $97.10
Upside: +13.29%
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $38.22
Upside: +25.59%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $10.45
Upside: +187.08%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $29.65
Upside: +34.91%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $0.73
Upside: +3,039.07%